To evaluate temporal trends and betweenhospital variation in off-label antipsychotic medication (APM) use in older adults undergoing cardiac surgery. DESIGN: Retrospective cohort study. SETTING: National administrative database including 465 U.S. hospitals. PARTICIPANTS: Individuals aged 65 and older without known indications for APMs who underwent cardiac surgery from 2004 to 2014 (N5293,212). MEASUREMENTS: Postoperative exposure to any APMs and potentially excessive dosing were examined. Hospitallevel APM prescribing intensity was defined as the proportion of individuals newly treated with APMs in the postoperative period. RESULTS: The rate of APM use declined from 8.8% in 2004 to 6.2% in 2014 (p<.001). Use of haloperidol (parenteral 7.0% to 4.5%, p<.001; oral: 1.9% to 0.5%, p<.001), and risperidone (1.1% to 0.3%, p<.001) declined, whereas quetiapine use tripled (0.6% to 1.9%, p5.03). Hospital APM prescribing intensity varied widely, from 0.3% to 35.6%, across 465 hospitals. Treated individuals at higher-prescribing hospitals were more likely to receive APMs on the day of discharge (highest vs lowest quintile: 15.1% vs 9.6%; p<.001) and for a longer duration (4.8 vs 3.7 days; p<.001) than those at lowerprescribing hospitals. Delirium was the strongest risk factor for APM exposure (odds ratio59.73, 95% confidence interval59.02-10.5), whereas none of the hospital characteristics were significantly associated. The rate of potentially excessive dosing declined (60.7% to 44.9%, p<.001), and risk factors for potentially excessive dosing were similar to those for any APM exposure. CONCLUSIONS: Our findings suggest highly variable prescribing cultures and raise concerns about inappropriate use, highlighting the need for better evidence to guide APM prescribing in hospitalized older adults after cardiac surgery. J Am Geriatr Soc 2018.
Documenting the trends and individual and hospital characteristics associated with off-label APM use is an essential step to reduce excessive APM use in these individuals.
This retrospective study was conducted to determine longitudinal trends and variation in postoperative off-label APM use in a national database of nearly 300,000 older adults undergoing cardiac surgery at 465 U.S. hospitals from 2004 to 2014. We hypothesized that a downward trend similar to that seen nursing homes would be observed in these individuals.
METHODS

Data Source
The Premier Healthcare Database is an administrative dataset that contains billing and coding information on inpatients treated at more than 700 hospitals, accounting for 20% of all hospitalizations in the United States. 24 Demographic information, admission and discharge status, diagnoses, medications (including dosages), procedures, diagnostic tests, and hospital characteristics are recorded. We analyzed data from 2004 to 2014 to examine the temporal trend of APM use in individuals undergoing cardiac surgery. Because this study involved analysis of de-identified data, the Brigham and Women's Hospital institutional review board determined that it qualified for a human subject research exemption. A waiver for informed consent was granted.
Study Population
We included individuals aged 65 and older who underwent coronary artery bypass grafting (International Classification of Diseases, Ninth Revision (ICD-9) procedure codes 36.1x), valve surgery (ICD-9 procedure codes: 35.2x), or both. Individuals with schizophrenic disorders (ICD-9 diagnosis codes: 295, V11.0), mood disorders (296), delusional disorders (297.1), nonorganic psychoses (298), Tourette's disorder (307.23), Huntington disease (333.4), hiccup (786.8), or chemotherapy (V58.1, V66.2, V67.2) were excluded. We also excluded individuals treated with an APM before surgery to focus on new postoperative APM use, and those treated on the day of surgery who might have received APMs for postoperative nausea and vomiting. Because of the possibility of incomplete reporting, we excluded data from hospitals that reported fewer than 20 cases in a given year.
APM Prescribing Characteristics
Postoperative APM exposure was defined using datestamped billing codes for a conventional (typical) APM (haloperidol) or newer (atypical) APMs (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone). These APMs were chosen based on clinical trials of delirium prevention and treatment and common use in routine practice for this indication 7, 25, 26 ; other APMs that are typically used as antiemetics were excluded. In our prior work, 27 postoperative APM use has 99% specificity and 92% positive predictive value to identify delirium when validated against the Confusion Assessment Method 28 in individuals undergoing cardiac surgery. Information on treatment duration and total daily dose was extracted. Because there is no APM dosing guideline for hospitalized individuals or those with delirium, we followed a previously used approach 29 that defined potentially excessive dosing according to dosing guidelines in the CMS long-term care manual for individuals with dementia (haloperidol >2 mg/d, olanzapine >5 mg/d, quetiapine >150 mg/d, risperidone >2mg/d, aripiprazole >10 mg/d. 30 Potentially excessive dosing for ziprasidone, which was not included in the CMS manual, was defined as more than 160 mg/d, the maximum maintenance dose. 31 We also examined first APM exposure in the intensive care unit (ICU), exposure on the day of discharge, and treatment duration longer than 7 days.
Hospital APM Prescribing Intensity
Hospital APM prescribing intensity was defined as the proportion of individuals newly treated with APMs in the postoperative period at each hospital estimated from a mixed-effects logistic model that included hospital identifier as a normally distributed random intercept. These predicted intercepts are empirical Bayes estimates that account for random variation. 32 Hospitals were classified into quintiles (4.4%, 4.5-5.7%, 5.8-7.3%, 7.4-9.4%, 9.5%). We also estimated adjusted prescribing intensity from a mixed-effects model that included individual and hospital characteristics (listed below). This represents the variation across hospitals that individual and hospital characteristics do not explain.
Individual and Hospital Characteristics
We examined the following variables that might affect a person's risk of APM exposure based on clinical knowledge and previous literature 22, 33, 34 : age, sex, race, insurance, admission type, type of surgery, dementia, and delirium. Previously validated coding algorithms were used to identify dementia (sensitivity 32%, specificity 100%, positive predictive value 96%, negative predictive value 98%) 35 and delirium (sensitivity 20%, specificity 99%, positive predictive value 91%, negative predictive value 66%). 27 The Charlson Comorbidity Index was calculated. 36 We measured clinical outcomes that APMs might affect, such as length (days) of index hospitalization, cardioversion or cardiopulmonary resuscitation, and inhospital mortality. We also characterized hospitals in terms of number of beds, teaching status, location (urban vs rural), and geographical area. The hospital ICU model was defined as ICU type (cardiac, cardiovascular, surgical, general or medical) that most individuals undergoing cardiac surgery at each hospital used during the study period.
Statistical Analysis
We examined longitudinal trends of off-label APM use by summarizing APM prescribing rates and characteristics over the calendar year and periods (2004-06, 2007-09, 2010-12, 2013-14) . A time trend was examined by including a linear term for time period in the generalized estimating equation (GEE) logistic regression model to account for clustering of individuals within hospitals. We also assessed whether longitudinal trends were consistent across subgroups defined according to age, sex, race, delirium diagnosis, or comorbidity burden and examined variation in unadjusted and adjusted APM prescribing rates among 465 hospitals. Individual and hospital characteristics were compared for hospitals in different APM prescribing quintiles using the Kruskal-Wallis test and chisquare test. We tested whether individuals treated at higher-prescribing hospitals had worse outcomes than those at lower-prescribing hospitals using GEE Poisson regression for mean length of hospitalization and GEE logistic regression for cardioversion or cardiopulmonary resuscitation and in-hospital mortality. To identify predictors of exposure to any APM dose and potentially excessive dose, we used GEE logistic regression models that included the above-listed patient and hospital characteristics, except for outcome variables. Finally, we performed 2 sensitivity analyses. Because a change in hospitals included in the dataset over time could have affected longitudinal trends, we examined trends using data from 163 hospitals that contributed data for at least 3 of the 4 periods. We also repeated the analysis without excluding 1,193 individuals who received an APM on the day of surgery. Analyses were conducted using R software version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.) Two-sided p<.05 was considered statistically significant.
RESULTS
Longitudinal Trends in Postoperative APM Use
Our study population included 293,212 individuals from 465 hospitals who underwent cardiac surgery and were not using APMs while in the hospital before or on the day of surgery (Supplementary Figure S1) . The overall rate of APM use in this population was 7.3%, declining from 8.8% in 2004 to 6.2% in 2014 (p<.001), a 30% relative decrease ( Figure 1 ). Reductions in use of haloperidol (parenteral: 7.0% to 4.5%, p<.001; oral: 1.9% to 0.5%, p<.001) and risperidone (1.1% to 0.3%, p<.001) drove this trend; quetiapine use rose steeply (0.6% to 1.9%, p5.03). This trend was consistent across subgroups defined according to age, sex, race, delirium diagnosis, and comorbidity burden and in sensitivity analyses that included only hospitals contributing data for 3 or more calendar periods and that included people treated on the day of surgery (data not shown).
A large majority of APM-treated individuals (Table 1 ) received haloperidol (85.6%). Common choice for atypical APMs shifted from risperidone (10.4%) in 2004-06 to quetiapine (29.1%) in 2013-14. There were declines in mean daily doses of haloperidol, quetiapine, and ziprasidone, whereas the mean daily dose of the other APMs remained essentially unchanged. The rate of potentially excessive dosing (per 100 person-days) was 56.0%, with the highest rate for haloperidol (91.1%). The rate declined from 60.7% to 44.9% (p<.001), particularly for quetiapine (9.4% to 3.3%; p<.001) and aripiprazole (52.5% to 13.3%; p<.001). Most treated individuals initiated APMs in the ICU, and 1 in 8 treated individuals received APMs on the day of discharge. Mean treatment duration was 4.6 days, and 15.5% received APMs for longer than 7 days. These patterns were consistent throughout the study period.
Hospital-Level Variation in Postoperative APM Use
Hospital APM prescribing intensity varied substantially, from 0.3% to 35.6% across 465 hospitals (Figure 2 ). Adjustment for individual and hospital characteristics modestly reduced the variation (0.1% to 29.5%). There were noteworthy differences in prescribing characteristics between hospitals in different APM prescribing quintiles (Supplementary Table S1 ). Higher-prescribing hospitals used more haloperidol (highest vs lowest quintile: 87.4% vs 81.3%; p<.001) and quetiapine (19.9% vs 12.8%; p<.001). Individuals treated at higher-prescribing hospitals were less likely than those in lower-prescribing hospitals to initiate APMs in the ICU (78.0% vs 83.0%) but were more likely to be treated on the day of discharge (15.1% vs 9.6%) and for a longer duration (4.8 vs 3.7 days) (p<.001 for all comparisons). Individuals were more likely to be nonwhite ( 
Individual and Hospital Characteristics Associated with APM Exposure
Individual characteristics that were positively associated with APM exposure were aged 75 and older, Medicaid (vs Medicare), urgent or emergency surgery, valve or combined surgery, dementia, delirium, and high comorbidity burden (Table 2 ). Of these, delirium was the strongest risk factor for APM exposure (odds ratio59.73; 95% confidence interval59.02-10.5). Female sex and commercial insurance were associated with less APM exposure. None 
DISCUSSION
To our knowledge, this is the first study to examine temporal trends and variation in off-label APM use in a nationwide sample of older adults undergoing cardiac surgery over 11 years. Despite a downward trend, 6.2% of individuals were treated with APMs after cardiac surgery in 2014, which corresponds to almost 10,000 people. 37 Although haloperidol was the most commonly prescribed APM, we observed a shift in choice of atypical APMs from risperidone to quetiapine. The steep increase in quetiapine use and consistently high rate of potentially excessive dosing of haloperidol are worrisome, particularly in light of recent guidelines highlighting the lack of consistent evidence of the benefit of APMs for delirium [4] [5] [6] and their potential harm. 7, 38 One in 8 treated individuals received an APM on the day of discharge, which may indicate continued exposure after discharge. Moreover, the wide unexplained variation of APM use across hospitals suggests different prescribing cultures and raises concerns about inappropriate use. 33 Our results underscore a need to promote more judicious APM use in the postoperative period after cardiac surgery.
Previous research on off-label APM prescribing has been mainly conducted in older adults with dementia and nursing home residents. A recent national survey of U.S. nursing homes reported a decreasing trend in off-label APM use, from 24% in 2011 to 16% in 2016. 22 Facility-level prescribing rates in 2005 ranged from 24% or less in the lowest prescribing quintile to 44% or more in the highest. 34 A 2003 study of nursing homes in Ontario, Canada, showed a similar variation in APM use, from 21% in the lowest quintile to 44% in the highest. 33 Most residents received atypical APMs (quetiapine, risperidone, olanzapine). 32, 33, 39 Risk of death and other serious adverse events has been documented for typical and atypical APMs.
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The use of APMs in hospitalized individuals without psychiatric illnesses has been investigated in only a few studies. Two single-center studies found a similar 9% rate of off-label APM use during nonpsychiatric hospitalization. 40, 41 Atypical APMs were more commonly prescribed than haloperidol and more likely to be continued at discharge. 40 In another U.S. was one-year point-prevalence study, not multi-year study that analyzed more than 2.6 million nonpsychiatric hospitalizations, APMs were prescribed to 6% of medical and surgical patients. 29 Although the rate of APM use was higher in medical patients, because there was a higher volume of surgical admissions, a larger absolute number of surgical patients received APMs than did medical patients. The prescribing rate ranged from 3% in the lowest prescribing quintile to 9% in the highest. As in the present study, characteristics of individuals treated at various hospitals did not fully explain this variation. 29 The risk of adverse events associated with APMs in hospitalized individuals undergoing surgery may differ from the risk associated with APM use in individuals with dementia because treatment duration is usually shorter when APMs are used to treat delirium. Hospitalized individuals undergoing cardiac surgery may have different vulnerability to adverse events than individuals with dementia. Nonetheless, safety data in hospitalized individuals are limited. In a recent study of 3,706 individuals treated off label with APMs after cardiac surgery, typical and atypical APMs were equally harmful in terms of death, cardiac arrhythmia, and pneumonia; moreover, the risk of adverse neurological events was higher for atypical APMs, particularly quetiapine, than haloperidol. 42 Clinical trials had limited statistical power to examine adverse events. 7, 8 Our study raises several concerns about the recent prescribing trends of APMs in the period after cardiac surgery. Although the observed downtrend coincides with publication of safety studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and the Food and Drug Administration boxed warnings for atypical APMs in 2005 43 and typical APMs in 2008 44 in older people with dementia, quetiapine use tripled. Quetiapine has antihistamine and antiserotonergic properties, which can cause sedation. We speculate that low-dose quetiapine may be increasingly used for insomnia 45 -a highly prevalent condition in hospitalized individuals 46, 47 and an important risk factor for delirium 48 -despite its unclear efficacy and potential harms. 49 Moreover, potentially excessive dosing was prevalent, particularly for haloperidol. Although the CMS long-term care dosing guideline 30 may not be appropriate for hospitalized individuals, the harmful effects of APMs are generally greater with higher doses. 10, 11 The variation in APM use in our study (highest vs lowest quintile: 14% vs 3%) was greater than the previously reported variation in the overall hospitalized population (9% vs 3%). 29 This may represent more variability in the clinical approach to prescribing APMs of providers in cardiac surgical services than in nonsurgical services. Individuals treated at higher-prescribing hospitals were more likely to initiate APMs outside the ICU and to be treated for longer and at discharge. Longer duration of hospitalization and higher rate of cardioversion or cardiopulmonary resuscitation were also worrisome, although these small differences might have been due to incomplete adjustment for individual characteristics. Finally, delirium was the strongest risk factor for APM use, which suggests that delirium prevention is crucial to reduce off-label APM exposure.
There are several caveats to consider in interpreting our study. First, the Premier Database does not contain information about outpatient medication use or indications for APM use. Some use might have been clinically appropriate. In addition, off-label use or doses higher than the CMS long-term care guideline may be justified for management of severe symptoms of delirium that can cause harm or interrupt life-sustaining treatments. Second, the dose of APMs recorded in the database may not be the actual dose administered. If a partial dose (e.g., less than a full vial of intravenous haloperidol) had been administered, the daily dose could have been overestimated. Moreover, we were unable to distinguish a scheduled dose from an as-needed dose. Third, diagnoses recorded in the Premier Database may not have been accurate or complete. For instance, hyperactive delirium is more likely to be recorded than hypoactive delirium. 27 Diagnoses from the index hospitalization may not have adequately captured relevant chronic conditions for accurate estimation of CCI. As a result, some hospital-level variation might have been due to different individual characteristics or hospital practice (e.g., systematic delirium screening) that were not measured. Finally, it is unclear whether our findings can be extended to individuals undergoing other major surgeries.
In hospitalized older adults after cardiac surgery, rates of off-label APM use and potentially excessive dosing has declined, but substantial hospital-level variation and a rapidly increasing trend in quetiapine use are troubling. Further research is needed to examine whether less use of APMs resulted in greater use of benzodiazepines or hypnotics. Continued use of APMs in the postacute settings warrants additional research. because our findings predate the recent guidelines from the Society of Critical Care Medicine 5 and the American Geriatrics Society Expert Panel, 6 it will be useful to examine future prescribing trends to assess their effect. To promote appropriate APM prescribing and improve clinical outcomes of older adults undergoing cardiac surgery, high-quality evidence on the effectiveness and harm of APMs for management of delirium and training of healthcare providers about effective nonpharmacological interventions 50 are urgently needed.
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